New Blood Biomarkers Differentiate Alzheimer’s Risk by Disease Stage
Recent studies find plasma p‑tau217 best detects clinical Alzheimer’s while amyloid‑beta misfolding and combined marker panels identify risk years earlier, shaping screening and trial approaches.
Overview
- Researchers report that p‑tau217 in blood is highly accurate at diagnosing Alzheimer’s once symptoms appear and adds useful medium‑term prognostic information for people with mild cognitive impairment or dementia.
- A long‑term analysis of 779 people in the ESTHER cohort found amyloid‑beta protein misfolding predicted future dementia in asymptomatic individuals better than p‑tau217, reaching an AUC near 0.79 for preclinical risk.
- Combining misfolding measures with demographic, genetic, and other blood markers produced stronger long‑term prediction, with a multi‑marker panel achieving an AUC of about 0.87 in the ESTHER analysis.
- Despite promise for earlier detection and more efficient trial recruitment, experts caution these tests remain mainly research tools because assays lack standardisation, population validation, and clear clinical thresholds.
- Clinically, earlier molecular detection could let patients manage risk factors, plan care, and qualify for early-stage therapies, but access, cost, diverse validation, and evidence that biomarker‑guided treatment improves outcomes must be resolved first.